Release Documentation. Upon compliance with the conditions to release of all or any portion of the Collateral set forth in Section 11.02, the Collateral Agent and the Trustee shall forthwith take all necessary action (at the written request of and the expense of the Company, accompanied by an Officers’ Certificate and Opinion of Counsel that the conditions precedent to such release have been satisfied) to release and re-convey to the applicable Collateral Grantor the applicable portion of the Collateral that is authorized to be released pursuant to Section 11.02, and shall deliver such Collateral in its possession to the applicable Collateral Grantor, including, without limitation, executing and delivering releases and satisfactions wherever required.
Release Documentation. If requested by Buyer, Seller shall have delivered to Buyer (a) with respect to a Correspondent Mortgage Loan, a bailee letter from the third party originator or its designee; (b) with respect to a Mortgage Loan that has been subject to a third party warehouse agreement (as approved by Buyer), a release from the related warehouse lender and (c) with respect a Mortgage Loan that Buyer is purchasing directly from Seller (as approved by Buyer), a release from Seller, in each case in form and substance acceptable to Buyer in its sole discretion.
Release Documentation. Upon compliance with the conditions to release of all or any portion of the Collateral set forth in Section 11.02, the Collateral Agent and the Trustee shall forthwith take all necessary action (at the request of and the expense of the Company, accompanied by an Officer’s Certificate and Opinion of Counsel that the conditions precedent to such release have been satisfied) to release and re-convey to the applicable Collateral Grantor or the Company the applicable portion of the Collateral that is authorized to be released pursuant to Section 11.02, and shall deliver such Collateral in its possession to the applicable Collateral Grantor or the Company, including, without limitation, executing and delivering releases and satisfactions wherever required. Neither the Trustee nor the Collateral Agent shall be liable for any such release undertaken in reliance upon any such Officer’s Certificate or Opinion of Counsel, and the Trustee and the Collateral Agent shall not be under any obligation to release any such Lien and security interest, or execute and deliver any such instrument of release, satisfaction or termination, unless and until it receives such Officer’s Certificate and Opinion of Counsel.
Release Documentation. Upon compliance with the conditions to release of all or any portion of the Collateral set forth in Section 12.05, and subject to the terms and conditions of the Collateral Trust Agreement, the Collateral Trustee and the Trustee shall forthwith take all necessary action (at the written request of and the expense of the Company, accompanied by an Officer’s Certificate and Opinion of Counsel to the effect that the conditions precedent to such release have been satisfied) to release and re-convey to the Company or any other Grantor, as the case may be, the applicable portion of the Collateral that is authorized to be released pursuant to Section 12.05, and shall deliver such Collateral in its possession to the Company or any other Grantor, as the case may be, including, without limitation, executing and delivering releases and satisfactions wherever required.
Release Documentation. The Batch/Lot Release Document Package will include a Certificate of Analysis and a Certificate of Compliance. Certificate of Analysis (CoA) A CoA will be provided and will include the name of the PRODUCTS, batch number, date of manufacture, and analytical specifications. The CoA will list the Release tests performed by Fresenius laboratories and actual test results.
Release Documentation. Subject to compliance with the conditions to release of all or any portion of the Collateral set forth in Section 12.06(a) or (b), and subject to the terms and conditions of the Collateral Agency Agreement, upon request of the Company, the Collateral Trustee will execute (with such acknowledgements and/or notarizations as are required) and deliver written evidence of such release (and any related Collateral in its possession or control) to the Company; provided, however, to the extent the Company requests the Collateral Trustee to deliver written evidence of the release of Collateral (or any such Collateral in its possession or control) in accordance with this Section 12.07, the Company will deliver to the Collateral Trustee (i) an Officers’ Certificate to the effect that such release of Collateral pursuant to the provisions described in this paragraph does not violate the terms of any Senior Secured Lien Document and (ii) an Opinion of Counsel to the Company stating that all conditions precedent to such release of Collateral have been satisfied or will be satisfied substantially concurrently with the delivery of such Opinion of Counsel.
Release Documentation. All Drug Substance shall meet the Specifications and shall be subjected to a quality control inspection and final release by Nisso. Nisso, at its cost, shall complete the manufacture, inspect and complete all necessary testing and other functions for each batch of the Drug Substance to demonstrate conformance to the warranties provided in Section 6.5 (Warranties) hereof prior to the release of the Drug Substance for shipment, all in accordance with Nisso’s quality control standards and in compliance with cGMPs. Nisso shall provide to Replidyne prompt written notice of such release, and shall include a packing list and documents in each shipment of the Drug Substance providing the following information and such other information as may be reasonably requested by Replidyne from time to time (“Release Documentation”): (i) Purchase Order number; (ii) Drug Substance code; (iii) quantity; (iv) Nisso lot number; (v) a certificate of analysis for each batch of the Drug Substance (which shall contain, at a minimum, analytical tests and results, date of manufacture, date of re-control (or shelf-life of the batch), batch size (total amount produced), a release statement, and a certification that the analytical tests are performed in accordance with the United States Pharmacopoeia); (vi) a certificate of compliance for each batch of the Drug Substance (confirming that the Drug Substance was manufactured in accordance with cGMPs); (vii) the results of all relevant testing data for each batch of the Drug Substance; and (viii) if required by Replidyne, samples of each batch of the Drug Substance (which shall be included in the quantities ordered by Replidyne under the relevant Purchase Order) for Replidyne’s independent testing pursuant to Section 4.8 (Inspection, Shortages and Defects) hereof (the reasonable shipping costs of such samples shall be for the account of Replidyne), which shall be reasonably satisfactory to Replidyne. Nisso shall also mail (i) copies of such packing list and documents to the shipping destination and to Replidyne, and (ii) such samples to Replidyne, for each shipment at the time of shipment. Nisso shall also notify Replidyne of rejected batches of the Drug Substance with the reasons for such rejection, and upon Replidyne’s request shall provide copies of Nisso’s internal documents related to deviation investigations.
Release Documentation. On or prior to the Closing Date, Remainco shall provide to RMT Partner guarantee and/or lien release documentation as may be necessary or advisable to release the Spinco Companies as borrowers or guarantors, as applicable, under any existing indebtedness for borrowed money of Remainco and its Subsidiaries (including under the Remainco Debt Facilities) and the release and termination of any and all Encumbrances granted in connection with such indebtedness, on the assets of Spinco Assets and the Spinco Companies, in each case, in form and substance reasonably satisfactory to RMT Partner (collectively, the “Lien and Guarantee Release”); provided that Remainco shall provide drafts of such Lien and Guarantee Release documentation at least three (3) Business Days prior to the Closing Date.
Release Documentation. In connection with any termination or release pursuant to this Article 9, the Administrative Agent shall execute and deliver to any Grantor, at such Grantor’s expense, all documents that such Grantor shall reasonably request to evidence such termination or release so long as the applicable Grantor shall have provided the Administrative Agent such certifications or documents as the Administrative Agent shall reasonably request in order to demonstrate compliance with the relevant provisions of this Article 9. Any execution and delivery of documents by the Administrative Agent pursuant to this Section shall be without recourse to or warranty by the Administrative Agent.
Release Documentation. Each Credit Party shall provide evidence of registration (where applicable) of the release of the Released Liens through the delivery of a no-lien certificate or equivalent documentation, issued by the relevant registration office (including without limitation, to the extent applicable, the RPPC, the Telecommunications Registry (Registro de Telecomunicaciones) maintained by COFETEL and the Mexican Institute of Industrial Property (Instituto Mexicano de Propiedad Industrial) within 180 days from the filing of the Release Documentation with such registration office on or before January 15, 2007 (or such later date as the Administrative Agent shall approve).
